Literature DB >> 22851707

Endothelial cells and fibroblasts amplify the arthritogenic type I IFN response in murine Lyme disease and are major sources of chemokines in Borrelia burgdorferi-infected joint tissue.

Robert B Lochhead1, F Lynn Sonderegger, Ying Ma, James E Brewster, Doug Cornwall, Heather Maylor-Hagen, Jennifer C Miller, James F Zachary, John H Weis, Janis J Weis.   

Abstract

Localized elevation in type I IFN has been uniquely linked to the severe Lyme arthritis that develops in C3H mice infected with the spirochete Borrelia burgdorferi. In this study, the dynamic interactions that result in generation of these responses were further examined in C3H mice carrying the type I IFN receptor gene ablation, which effectively blocks all autocrine/paracrine signaling crucial to induction of downstream effectors. Reciprocal radiation chimeras between C3H and IFNAR1⁻/⁻ mice implicated both radiation-sensitive and radiation-resistant cells of the joint tissue in the proarthritic induction of type I IFN. Ex vivo analysis of cells from the naive joint revealed CD45⁺ cells residing in the tissue to be uniquely capable of initiating the type I IFN response to B. burgdorferi. Type I IFN responses were analyzed in real time by lineage sorting of cells from infected joint tissue. This demonstrated that myeloid cells, endothelial cells, and fibroblasts were responsible for propagating the robust IFN response, which peaked at day 7 postinfection and rapidly resolved. Endothelial cells and fibroblasts were the dominant sources of IFN signature transcripts in the joint tissue. Fibroblasts were also the major early source of chemokines associated with polymorphonuclear leukocyte and monocyte/macrophage infiltration, thus providing a focal point for arthritis development. These findings suggest joint-localized interactions among related and unrelated stromal, endothelial, and myeloid cell lineages that may be broadly applicable to understanding the pathogeneses of diseases associated with type I IFN signature, including systemic lupus erythematosus and some rheumatoid arthritides.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22851707      PMCID: PMC3424307          DOI: 10.4049/jimmunol.1201095

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  61 in total

1.  Synovial fibroblasts of patients with rheumatoid arthritis attach to and invade normal human cartilage when engrafted into SCID mice.

Authors:  U Müller-Ladner; J Kriegsmann; B N Franklin; S Matsumoto; T Geiler; R E Gay; S Gay
Journal:  Am J Pathol       Date:  1996-11       Impact factor: 4.307

2.  Cross-regulation of TNF and IFN-alpha in autoimmune diseases.

Authors:  A Karolina Palucka; Jean-Philippe Blanck; Lynda Bennett; Virginia Pascual; Jacques Banchereau
Journal:  Proc Natl Acad Sci U S A       Date:  2005-02-22       Impact factor: 11.205

3.  The role of CD14 in signaling mediated by outer membrane lipoproteins of Borrelia burgdorferi.

Authors:  R M Wooten; T B Morrison; J H Weis; S D Wright; R Thieringer; J J Weis
Journal:  J Immunol       Date:  1998-06-01       Impact factor: 5.422

4.  The nervous system as ectopic germinal center: CXCL13 and IgG in lyme neuroborreliosis.

Authors:  Kavitha Narayan; Donna Dail; Libin Li; Diego Cadavid; Sheela Amrute; Patricia Fitzgerald-Bocarsly; Andrew R Pachner
Journal:  Ann Neurol       Date:  2005-06       Impact factor: 10.422

5.  Dual role of interleukin-10 in murine Lyme disease: regulation of arthritis severity and host defense.

Authors:  J P Brown; J F Zachary; C Teuscher; J J Weis; R M Wooten
Journal:  Infect Immun       Date:  1999-10       Impact factor: 3.441

6.  Rapid and sensitive quantification of Borrelia burgdorferi-infected mouse tissues by continuous fluorescent monitoring of PCR.

Authors:  T B Morrison; Y Ma; J H Weis; J J Weis
Journal:  J Clin Microbiol       Date:  1999-04       Impact factor: 5.948

7.  Experimental lyme arthritis in the absence of interleukin-4 or gamma interferon.

Authors:  C R Brown; S L Reiner
Journal:  Infect Immun       Date:  1999-07       Impact factor: 3.441

8.  Functional role of type I and type II interferons in antiviral defense.

Authors:  U Müller; U Steinhoff; L F Reis; S Hemmi; J Pavlovic; R M Zinkernagel; M Aguet
Journal:  Science       Date:  1994-06-24       Impact factor: 47.728

9.  Identification of quantitative trait loci governing arthritis severity and humoral responses in the murine model of Lyme disease.

Authors:  J J Weis; B A McCracken; Y Ma; D Fairbairn; R J Roper; T B Morrison; J H Weis; J F Zachary; R W Doerge; C Teuscher
Journal:  J Immunol       Date:  1999-01-15       Impact factor: 5.422

10.  Gene-expression signatures: biomarkers toward diagnosing multiple sclerosis.

Authors:  J T Tossberg; P S Crooke; M A Henderson; S Sriram; D Mrelashvili; S Chitnis; C Polman; S Vosslamber; C L Verweij; N J Olsen; T M Aune
Journal:  Genes Immun       Date:  2011-09-22       Impact factor: 2.676

View more
  17 in total

1.  Robust interferon signature and suppressed tissue repair gene expression in synovial tissue from patients with postinfectious, Borrelia burgdorferi-induced Lyme arthritis.

Authors:  Robert B Lochhead; Sheila L Arvikar; John M Aversa; Ruslan I Sadreyev; Klemen Strle; Allen C Steere
Journal:  Cell Microbiol       Date:  2018-10-17       Impact factor: 3.715

2.  MicroRNA Expression Shows Inflammatory Dysregulation and Tumor-Like Proliferative Responses in Joints of Patients With Postinfectious Lyme Arthritis.

Authors:  Robert B Lochhead; Klemen Strle; Nancy D Kim; Minna J Kohler; Sheila L Arvikar; John M Aversa; Allen C Steere
Journal:  Arthritis Rheumatol       Date:  2017-05       Impact factor: 10.995

3.  Interferon-gamma production in Lyme arthritis synovial tissue promotes differentiation of fibroblast-like synoviocytes into immune effector cells.

Authors:  Robert B Lochhead; David Ordoñez; Sheila L Arvikar; John M Aversa; Luke S Oh; Benton Heyworth; Ruslan Sadreyev; Allen C Steere; Klemen Strle
Journal:  Cell Microbiol       Date:  2019-01-04       Impact factor: 3.715

4.  Induction of indoleamine 2,3-dioxygenase by Borrelia burgdorferi in human immune cells correlates with pathogenic potential.

Authors:  Andrea C Love; Ira Schwartz; Mary M Petzke
Journal:  J Leukoc Biol       Date:  2014-11-24       Impact factor: 4.962

5.  Borrelia burgdorferi arthritis-associated locus Bbaa1 regulates Lyme arthritis and K/B×N serum transfer arthritis through intrinsic control of type I IFN production.

Authors:  Ying Ma; Kenneth K C Bramwell; Robert B Lochhead; Jackie K Paquette; James F Zachary; John H Weis; Cory Teuscher; Janis J Weis
Journal:  J Immunol       Date:  2014-11-05       Impact factor: 5.422

6.  A Highly Expressed Human Protein, Apolipoprotein B-100, Serves as an Autoantigen in a Subgroup of Patients With Lyme Disease.

Authors:  Jameson T Crowley; Elise E Drouin; Annalisa Pianta; Klemen Strle; Qi Wang; Catherine E Costello; Allen C Steere
Journal:  J Infect Dis       Date:  2015-05-26       Impact factor: 5.226

7.  Genetic Control of Lyme Arthritis by Borrelia burgdorferi Arthritis-Associated Locus 1 Is Dependent on Localized Differential Production of IFN-β and Requires Upregulation of Myostatin.

Authors:  Jackie K Paquette; Ying Ma; Colleen Fisher; Jinze Li; Sang Beum Lee; James F Zachary; Yong Soo Kim; Cory Teuscher; Janis J Weis
Journal:  J Immunol       Date:  2017-10-06       Impact factor: 5.422

8.  Innate Immune Memory to Repeated Borrelia burgdorferi Exposure Correlates with Murine In Vivo Inflammatory Phenotypes.

Authors:  Quentin Bernard; Linden T Hu
Journal:  J Immunol       Date:  2020-11-09       Impact factor: 5.422

Review 9.  Host transcriptome response to Borrelia burgdorferi sensu lato.

Authors:  Derick Thompson; John A Watt; Catherine A Brissette
Journal:  Ticks Tick Borne Dis       Date:  2020-12-13       Impact factor: 3.744

Review 10.  Lyme arthritis: linking infection, inflammation and autoimmunity.

Authors:  Robert B Lochhead; Klemen Strle; Sheila L Arvikar; Janis J Weis; Allen C Steere
Journal:  Nat Rev Rheumatol       Date:  2021-07-05       Impact factor: 32.286

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.